Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.[1] It targets TYRP1.[2]
Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.[2]
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 3.145.151.202